Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Saulius K. Girnius, Joshua Richter, Kimberly Bogard, Habte A. Yimer, Sudhir Manda, Roger M. Lyons, Stephen J. Noga, Robert M. Rifkin

Blood (2023) 142 (Supplement 1): 6677.

https://doi.org/10.1182/blood-2023-179795

Published: 2023

Journal Articles

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Blood (2023) 142 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2023-186997

Published: 2023

Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Blood (2023) 142 (Supplement 1): 6510.

https://doi.org/10.1182/blood-2023-180161

Published: 2023

Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 9269–9271.

https://doi.org/10.1182/blood-2022-167758

Published: 2022

Journal Articles

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Sudhir Manda, Bertrand Anz, III, Christopher Benton, E. Randolph Broun, Habte Yimer, John Renshaw, George F. Geils, Jr., Jose Cruz, Suzanne Fanning, Jason Melear, Jeff P. Sharman, Kingston Kang, Anders Svensson, Madhavi Pai, William Donnellan

Blood (2021) 138 (Supplement 1): 1265.

https://doi.org/10.1182/blood-2021-144886

Published: 2021

Journal Articles

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Robert M. Rifkin, Stephen J. Noga, Saulius K. Girnius, Kimberly Bogard, Sudhir Manda, Habte Yimer, Presley Whidden, Ruemu E. Birhiray, Philip Twumasi-Ankrah, Yikun Guo, Rami Owera, Leon Bernal-Mizrachi, Roger Lyons

Blood (2021) 138 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2021-150094

Published: 2021

Journal Articles

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Blood (2021) 138 (Supplement 1): 1420.

https://doi.org/10.1182/blood-2021-150025

Published: 2021

Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1410.

https://doi.org/10.1182/blood-2021-148544

Published: 2021

Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2021-147258

Published: 2021

Journal Articles

In -Class Transition ( i CT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Saulius K. Girnius, MD, Habte A. Yimer, MD, Stephen J. Noga, MDPhD, Sudhir Manda, MD, Roger M. Lyons, MD, Kimberly Bogard, PharmD, Presley Whidden, Dasha Cherepanov, Vickie Lu, PhD, Jack Aiello, EE, MS, BS, Joshua R. Richter, MD, Robert M. Rifkin, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140482

Published: 2020

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137406

Published: 2020

Journal Articles

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Robert M. Rifkin, MD, Sudhir Manda, MD, Stephen J Noga, MD PhD, Habte A Yimer, MD, Saulius K. Girnius, MD, Ruemu Ejedafeta Birhiray, MD, Christopher A. Yasenchak, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 1882.

https://doi.org/10.1182/blood-2019-124747

Published: 2019

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Stephen J Noga, MD PhD, Robert M. Rifkin, MD, Sudhir Manda, MD, Ruemu Ejedafeta Birhiray, MD, Roger M. Lyons, MD, Presley Whidden, Robert L. Schlossman, MD, Bingxia Wang, PhD, Ralph V. Boccia, MD

Blood (2019) 134 (Supplement_1): 3168.

https://doi.org/10.1182/blood-2019-124784

Published: 2019

Journal Articles

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Max J Gordon, MD, Stephen M Amrock, SM, MD, Xavier Issac Rivera, BS, Spencer James, MD, Sudhir Manda, MD, Stephen E Spurgeon, MD, Daniel Persky, MD, Alexey Danilov, MD PhD

Blood (2017) 130 (Supplement 1): 918.

https://doi.org/10.1182/blood.V130.Suppl_1.918.918

Published: 2017

Journal Articles

Impact of Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia: A Retrospective Analysis

Sudhir Manda, MD FACP, Spencer James, MS, Rebecca Wang, BS, Rajeev Krishnan, MD, Alexey V. Danilov, MD PhD

Blood (2014) 124 (21): 1312.

https://doi.org/10.1182/blood.V124.21.1312.1312

Published: 2014

NARROW

In -Class Transition ( i CT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Medical Comorbidities Assessed By CIRS Negatively Impact Survival in the Era of Targeted Therapies in CLL: A Multicenter Retrospective Analysis

Impact of Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia: A Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only